Business
Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference
MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and
About this update from Xencor, Inc.
[{"type":"text","content":" MONROVIA, Calif.--(BUSINESS WIRE)--\nXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 4:00 p.m. ET / 1:00 p.m. PT.\n\nA live webcast will be available under \"Events & Presentations\" in the Investors section of the Company's website located at www.xencor.com. Following the webcast, a replay will be archived on the website for at least 30 days.\n\nAbout Xencor, Inc.\n\nXencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210920005829/en/\n\nCharles Liles\[email protected]\n\nMedia Contact\nJason I. Spark\nCanale Communications\n619-849-6005\[email protected]\n\nSource: Xencor, Inc.","length":3142,"tagName":"div"}]